Sentiment-Signal
17,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 11.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appo |
| 06.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoi |
Stammdaten
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Unternehmen & Branche
| Name | ARTIVION, INC. |
|---|---|
| Ticker | AORT |
| CIK | 0000784199 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,68 Mrd. USD |
| Beta | 1,62 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 441,330,000 | 9,768,000 | 0.21 | 884,796,000 | 448,232,000 |
| 2025-09-30 | 10-Q | 113,388,000 | 6,502,000 | 0.13 | 857,662,000 | 438,694,000 |
| 2025-06-30 | 10-Q | 112,972,000 | 1,345,000 | 0.03 | 838,387,000 | 419,902,000 |
| 2025-03-31 | 10-Q | 98,978,000 | -505,000 | -0.01 | 791,163,000 | 294,252,000 |
| 2024-12-31 | 10-K | 388,537,000 | -13,359,000 | -0.32 | 789,101,000 | 276,200,000 |
| 2024-09-30 | 10-Q | 95,779,000 | -2,288,000 | -0.05 | 803,144,000 | 304,739,000 |
| 2024-06-30 | 10-Q | 98,019,000 | -2,121,000 | -0.05 | 789,539,000 | 295,056,000 |
| 2024-03-31 | 10-Q | 97,431,000 | 7,533,000 | 0.18 | 784,007,000 | 294,985,000 |
| 2023-12-31 | 10-K | 354,004,000 | -30,690,000 | -0.75 | 792,397,000 | 281,780,000 |
| 2023-09-30 | 10-Q | 87,854,000 | -9,801,000 | -0.24 | 774,787,000 | 271,975,000 |
| 2023-06-30 | 10-Q | 89,251,000 | -3,382,000 | -0.08 | 777,861,000 | 282,508,000 |
| 2023-03-31 | 10-Q | 83,229,000 | -13,532,000 | -0.33 | 757,073,000 | 279,917,000 |
| 2022-12-31 | 10-K | 313,789,000 | -19,192,000 | -0.48 | 762,798,000 | 284,329,000 |
| 2022-09-30 | 10-Q | 76,838,000 | -13,713,000 | -0.34 | 742,731,000 | 255,108,000 |
| 2022-06-30 | 10-Q | 80,340,000 | -4,259,000 | -0.11 | 764,864,000 | 281,509,000 |
| 2022-03-31 | 10-Q | 77,213,000 | -3,389,000 | -0.08 | 781,856,000 | 297,492,000 |
| 2021-12-31 | 10-K | 298,836,000 | -14,834,000 | -0.38 | 793,052,000 | 300,728,000 |
| 2021-09-30 | 10-Q | 72,207,000 | 10,582,000 | 0.26 | 818,654,000 | 311,541,000 |
| 2021-06-30 | 10-Q | 76,148,000 | -2,178,000 | -0.06 | 810,497,000 | 301,835,000 |
| 2021-03-31 | 10-Q | 71,087,000 | -3,138,000 | -0.08 | 794,832,000 | 297,331,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -8,962 | 38.00 | -340,556.00 | -109,8% | |
| 2026-03-03 | Mackin James P | Officer, President & CEO | Open Market Sale | -17,887 | 37.78 | -675,692.16 | -217,8% | |
| 2026-03-03 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -6,316 | 37.78 | -238,590.69 | -76,9% | |
| 2026-03-03 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -901 | 37.78 | -34,035.82 | -11,0% | |
| 2026-03-03 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,149 | 37.78 | -81,179.76 | -26,2% | |
| 2026-03-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -3,843 | 37.78 | -145,171.63 | -46,8% | |
| 2026-03-03 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -4,573 | 37.78 | -172,747.82 | -55,7% | |
| 2026-03-02 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,513 | 38.02 | -57,531.67 | -18,5% | |
| 2026-03-02 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -2,784 | 38.02 | -105,861.32 | -34,1% | |
| 2026-03-02 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -5,178 | 38.02 | -196,892.93 | -63,5% | |
| 2026-03-02 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -2,183 | 38.02 | -83,008.36 | -26,8% | |
| 2026-03-02 | Mackin James P | Officer, President & CEO | Open Market Sale | -14,911 | 38.02 | -566,989.28 | -182,7% | |
| 2026-03-02 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -641 | 38.02 | -24,373.96 | -7,9% | |
| 2026-02-24 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -830 | 35.69 | -29,625.19 | -9,5% | |
| 2026-02-24 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -2,075 | 35.69 | -74,062.98 | -23,9% | |
| 2026-02-24 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -4,485 | 35.69 | -160,083.11 | -51,6% | |
| 2026-02-24 | Mackin James P | Officer, President & CEO | Open Market Sale | -13,936 | 35.69 | -497,417.65 | -160,3% | |
| 2026-02-24 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -1,668 | 35.69 | -59,535.92 | -19,2% | |
| 2026-02-24 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,259 | 35.69 | -44,937.49 | -14,5% | |
| 2026-02-23 | Mackin James P | Officer, President & CEO | Open Market Sale | -20,962 | 37.59 | -787,919.66 | -253,9% | |
| 2026-02-23 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,423 | 37.59 | -91,075.72 | -29,4% | |
| 2026-02-23 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -3,773 | 37.59 | -141,819.52 | -45,7% | |
| 2026-02-23 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -3,079 | 37.59 | -115,733.45 | -37,3% | |
| 2026-02-23 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -4,981 | 37.59 | -187,225.83 | -60,3% | |
| 2026-02-23 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -1,731 | 37.59 | -65,064.83 | -21,0% | |
| 2025-12-15 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -5,000 | 45.11 | -225,550.00 | -72,7% | |
| 2025-12-08 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -4,572 | 44.42 | -203,083.67 | -65,5% | |
| 2025-12-03 | Mackin James P | Officer, President & CEO | Open Market Sale | -30,921 | 45.46 | -1,405,699.58 | -453,0% | |
| 2025-12-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -5,267 | 45.30 | -238,595.10 | -76,9% | |
| 2025-12-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -2,048 | 45.30 | -92,774.40 | -29,9% | |
| 2025-12-02 | Mackin James P | Officer, President & CEO | Open Market Sale | -30,921 | 45.56 | -1,408,729.84 | -454,0% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -8,370 | 45.35 | -379,537.65 | -122,3% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -5,715 | 45.35 | -259,152.39 | -83,5% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -14,586 | 44.92 | -655,188.53 | -211,2% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -18,705 | 44.91 | -840,041.55 | -270,7% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,355 | 44.28 | -59,996.69 | -19,3% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -11,888 | 44.14 | -524,736.32 | -169,1% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,033 | 44.32 | -90,092.40 | -29,0% | |
| 2025-11-18 | Hoff Elizabeth A | Director | Open Market Sale | -4,200 | 45.10 | -189,411.60 | -61,0% | |
| 2025-11-17 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -6,394 | 45.17 | -288,816.98 | -93,1% | |
| 2025-11-17 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6,394 | 45.17 | -288,816.98 | -93,1% | |
| 2025-11-17 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -6,000 | 45.73 | -274,380.00 | -88,4% | |
| 2025-11-14 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6,393 | 44.67 | -285,575.31 | -92,0% | |
| 2025-11-14 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -6,393 | 45.00 | -287,685.00 | -92,7% | |
| 2025-11-13 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -5,761 | 45.86 | -264,187.94 | -85,1% | |
| 2025-11-13 | Mackin James P | Officer, President & CEO | Open Market Sale | -34,210 | 45.86 | -1,568,802.18 | -505,6% | |
| 2025-11-13 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6,563 | 45.86 | -300,966.05 | -97,0% | |
| 2025-11-13 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -3,482 | 45.86 | -159,677.56 | -51,5% | |
| 2025-11-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -4,993 | 45.86 | -228,968.99 | -73,8% | |
| 2025-11-11 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -10,000 | 46.18 | -461,800.00 | -148,8% | |
| 2025-11-10 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -2,960 | 44.62 | -132,072.24 | -42,6% | |
| 2025-11-10 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2,566 | 44.62 | -114,492.35 | -36,9% | |
| 2025-11-10 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -1,789 | 44.62 | -79,823.39 | -25,7% | |
| 2025-11-10 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -3,373 | 44.62 | -150,499.89 | -48,5% | |
| 2025-11-10 | Mackin James P | Officer, President & CEO | Open Market Sale | -17,580 | 44.62 | -784,402.02 | -252,8% | |
| 2025-08-27 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -18,200 | 44.02 | -801,218.60 | -258,2% | |
| 2025-08-25 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -10,000 | 44.37 | -443,700.00 | -143,0% | |
| 2025-08-15 | Mackin James P | Officer, President & CEO | Open Market Sale | -12,500 | 42.32 | -528,987.50 | -170,5% | |
| 2025-08-12 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -10,802 | 43.67 | -471,755.75 | -152,0% | |
| 2025-08-12 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -16,975 | 43.01 | -730,111.73 | -235,3% | |
| 2025-08-12 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -6,381 | 43.02 | -274,497.86 | -88,5% | |
| 2025-08-08 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -7,992 | 38.49 | -307,612.08 | -99,1% | |
| 2025-06-17 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -13,764 | 29.50 | -406,038.00 | -130,9% | |
| 2025-06-17 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,236 | 29.50 | -36,462.00 | -11,8% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,253 | 28.47 | -35,668.65 | -11,5% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -14,306 | 28.42 | -406,600.84 | -131,0% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -8,747 | 28.46 | -248,952.74 | -80,2% | |
| 2025-06-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1,826 | 28.43 | -51,908.98 | -16,7% | |
| 2025-05-27 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -8,748 | 29.00 | -253,692.00 | -81,8% | |
| 2025-05-23 | SEMEDO ANTHONY B. | Director | Open Market Sale | -2,600 | 28.47 | -74,027.20 | -23,9% | |
| 2025-05-23 | SEMEDO ANTHONY B. | Director | Open Market Sale | -2,600 | 28.47 | -74,027.20 | -23,9% | |
| 2025-05-21 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -9,926 | 29.00 | -287,854.00 | -92,8% | |
| 2025-05-09 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -5,737 | 29.13 | -167,119.96 | -53,9% | |
| 2025-05-09 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -4,811 | 29.13 | -140,145.39 | -45,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.